Knight Cancer Institute

The OHSU Knight Cancer Institute is an international leader in cancer research and personalized cancer treatment. With the mission of ending cancer as we know it, the Knight Cancer Institute continues to build its scientific and clinical leadership and cancer treatment resources. Public support, including the State of Oregon, and private philanthropy have provided crucial resources to advance our progress.


OHSU Knight Cancer Institute Director Brian Druker, M.D.

Brian Druker, M.D. (2017)
Brian Druker, M.D.

Brian Druker, M.D., is the director of the Knight Cancer Institute. Druker helped usher in an era of personalized cancer medicine with his discovery that cancer cells could be shut down by disabling the molecules that drive their growth without harming healthy cells. The drug that resulted from that research, Gleevec®, revolutionized how cancer is treated. It also inspired a new wave of exploration of treatments that target cancer-causing molecules.


Cancer Early Detection Advanced Research Center (CEDAR)

CEDAR is the first large-scale early cancer detection program of its kind. The center's unique scientific research model is team-based, tackling problems from different angles to come up with creative solutions to cancer's biggest challenges. 

Sadik Esener, Ph.D.
Sadik Esener, Ph.D.

Nanotechnology expert Sadik Esener, Ph.D., leads CEDAR. He has extensive experience in bringing together scientists and technology across disciplines to provide compelling solutions to previously unsolved challenges in biomedicine. He has a strong track record in innovation; technology he developed launched many startup companies, including five from his labs in Southern California.


Precision Oncology

The OHSU Knight Cancer Institute, a pioneer in personalized cancer medicine, is an international leader in research and cancer treatment. Over the years, the Knight Cancer Institute has worked steadily to advance the field, fueled by philanthropic investments and led by renowned experts in melanoma, breast cancer, acute and chronic myeloid leukemia, genomics, immune cells, and more. 

Gordon Mills, M.D., Ph.D.
Gordon Mills, M.D., Ph.D.

One of the most highly cited scientists in the world, Gordon Mills, M.D., Ph.D., leads the institute’s efforts in precision oncology. Mills believes we are at an “inflection point” in changing the whole outcome for cancer patients, and sees his role as the director of the Precision Oncology program to be an integrative force across various efforts in progress at the institute, including the Cancer Early Detection Advanced Research (CEDAR) Center, immuno-oncology and the system biology groups.